Navigation Links
Among the Novel Oral Anticoagulants, Bayer/Janssen's Xarelto is Positioned To Be the Sales-Leading Therapy for Venous Thromboembolism (VTE)
Date:8/29/2013

BURLINGTON, Mass., Aug. 29, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that Bayer/Janssen's Xarelto will be the sales-leading therapy among the novel oral anticoagulants in the combined venous thromboembolism (VTE) markets. Xarelto benefits from its first-to-market advantage for VTE treatment/secondary prophylaxis, the removal of the need for bridging with a low-molecular-weight heparin in the VTE treatment/secondary prophylaxis setting and once-daily dosing. Bristol-Myers Squibb/Pfizer's Eliquis will be Xarelto's closest competitor, but its later launch in both the VTE primary prophylaxis and VTE treatment/secondary prophylaxis markets, as well as its twice-daily dosing, will likely limit its sales relative to Xarelto during the 2012 to 2022 forecast period.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The Pharmacor advisory service entitled Venous Thromboembolism forecasts that the combined markets for drugs used for both VTE primary prophylaxis and VTE treatment/secondary prophylaxis will grow to $7.3 billion in 2022 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The novel oral anticoagulants are forecast to continue to gain market share at the expense of low-molecular-weight heparins (LMWHs) for VTE prevention following orthopedic surgery. Uptake is higher in Europe where a greater number of novel oral anticoagulants are available for this indication. However, despite this increased uptake, the LMWHs remain the overall market leader in the major markets covered in the report; along with vitamin K antagonists (VKAs), LMWHs continue to dominate the VTE/secondary prophylaxis market, where Xarelto is the only novel oral anticoagulant to have gained approval.

The report also finds that while the failure of the novel oral anticoagulants investigated in clinical trials for VTE primary prophylaxis in the medically ill will limit the growth potential of the VTE market, the overall market will benefit from increased physician awareness of the need for VTE primary prophylaxis following non-orthopedic surgery. However, the main growth driver for the VTE market will be the anticipated launches of the novel oral anticoagulants for VTE treatment/secondary prophylaxis, as their use at the expense of VKAs will mark a paradigm shift in standard treatment practices during the forecast period.

"The anticipated launches of Eliquis, Boehringer Ingelheim's Pradaxa and Daiichi Sankyo's Lixiana for VTE treatment/secondary prophylaxis, along with the previously-approved Xarelto will drive growth of the VTE market through 2022," said Decision Resources Analyst Eamonn O'Connor, Ph.D. "Growth opportunities for these agents will be restricted to the treatment/secondary prophylaxis market, owing to these agents' inability, to date, to gain a primary prophylaxis label outside of the orthopedic surgery setting."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Prem Reddy Named Among Most Influential Physician Executives in Nation
2. Brain Research Foundation Announces Grant To Study Concussive Events Among Grade School Children
3. Imaging Healthcare Specialists Among the First in the Nation to Offer Imaging Diagnosis for Alzheimers Disease
4. Advanced Radiology Among the First in the U.S. to Offer New Alzheimers Disease Tracer
5. Social Norms, Life Changes and Increasing Pressures Contribute to Substance Abuse Among Adult Women
6. Frost & Sullivan: Miniaturization of Medical Devices Reduces Mortality Rates among Cardiac Dysrhythmia Patients
7. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
8. CBIS Releases Corporate Operational Guidance for 2013 as the Company Reorganizes to better meet the Growing Global Crisis Associated with Anti-Retroviral Drug Resistance among People with AIDS, as well as the Increasing Need for Patient Friendly Ski
9. Forbes Ranks SynCardia Among "Americas Most Promising Companies" for Second Straight Year
10. GNC NutriWater, COTYs Beyonce Pulse NYC, Swansons Super DPA Fish Oil, Among First SupplySide Insights Awards Finalists
11. Poorest U.S. States Rank Among Most Wasteful in Unnecessary Medication-Related Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016 Velano Vascular, a ... for hospitalized patients and their practitioners, announced today that ... funding. Velano will use the proceeds from this financing, ... completed in January 2015, to support the development and ... and pediatric populations. Philadelphia ...
(Date:2/8/2016)... Calif. , Feb. 8, 2016  HemaFlo Therapeutics, Inc. ... (USPTO) has issued US Patent Number 9,119,880 covering the use ... Dale Peterson , PhD, HemaFlo,s founder, said, "We are ... --> Dale Peterson , PhD, HemaFlo,s founder, ... a powerful technology." --> Dale Peterson ...
(Date:2/8/2016)... NORTHBROOK, Ill. , Feb. 8, 2016  Astellas Pharma ... today announced the promotion of James Robinson as ... the company,s operations in North and South America ... president, Astellas Pharma US, representing the commercial organization in ... assumed in 2013. Masao Yoshida , who ...
Breaking Medicine Technology:
(Date:2/8/2016)... , ... February 08, 2016 , ... Guruji Mahendra Kumar ... 10th and 11th, 2016 in honor of his birthday on February 10th. During ... Mahendra Trivedi is known by over 250,000 people from over 40 different countries ...
(Date:2/7/2016)... Metamora, Michigan (PRWEB) , ... February 07, 2016 ... ... pelvic organ prolapse with the latest techniques and the most minimally invasive approaches. ... pelvic organ prolapse, particularly after menopause. Other risk factors include surgery to the ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... has added Kybella® to his medical and surgical expertise. Technically known as deoxycholic ... injectable medication used as a non-surgical alternative for reduction of fat below the ...
(Date:2/6/2016)... ... ... With the FCPX LUT: Summer pack from Pixel Film Studios, ... is a Lookup Table that contains a mathematical formula for modifying an image. The ... manipulating each pixel, LUT's can change each color range differently, it gives the user ...
(Date:2/5/2016)... SARASOTA, Florida (PRWEB) , ... February 05, 2016 , ... ... an event he has completed every year since it started in 2003. This year, ... attracting the attention of fellow runners and NBA team the Miami Heat. , This ...
Breaking Medicine News(10 mins):